This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Feb;7(2):93-4.

doi: 10.1080/15265160601112253.

Faulty premise, premature conclusion: that money was extraneous to the research ethics of the TGN1412 study

Bethany Spielman¹

Affiliations

PMID: 17366212
DOI: 10.1080/15265160601112253

Comment

Faulty premise, premature conclusion: that money was extraneous to the research ethics of the TGN1412 study

Bethany Spielman. Am J Bioeth. 2007 Feb.

. 2007 Feb;7(2):93-4.

doi: 10.1080/15265160601112253.

Author

Bethany Spielman¹

Affiliation

¹ Department of Medical Humanities, Southern Illinois University, Springfield, IL 62794-9603, USA. bspielman@siumed.edu

PMID: 17366212
DOI: 10.1080/15265160601112253

No abstract available

PubMed Disclaimer

Comment on

Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial.
Emanuel EJ, Miller FG. Emanuel EJ, et al. Am J Bioeth. 2007 Feb;7(2):76-81. doi: 10.1080/15265160601111800. Am J Bioeth. 2007. PMID: 17366206 Review.

Similar articles

Adalimumab in juvenile rheumatoid arthritis.
Sfriso P, Ravaioli F. Sfriso P, et al. N Engl J Med. 2008 Dec 4;359(23):2495; author reply 2496-7. doi: 10.1056/NEJMc081987. N Engl J Med. 2008. PMID: 19052133 No abstract available.
Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.
Dayan CM, Wraith DC. Dayan CM, et al. Clin Exp Immunol. 2008 Feb;151(2):231-4. doi: 10.1111/j.1365-2249.2007.03559.x. Clin Exp Immunol. 2008. PMID: 18190459 Free PMC article. Review.
Establishing risk of human experimentation with drugs: lessons from TGN1412.
Kenter MJ, Cohen AF. Kenter MJ, et al. Lancet. 2006 Oct 14;368(9544):1387-91. doi: 10.1016/S0140-6736(06)69562-7. Lancet. 2006. PMID: 17046471 Review. No abstract available.
TGN1412--a regulator's perspective.
Schneider CK, Kalinke U, Löwer J. Schneider CK, et al. Nat Biotechnol. 2006 May;24(5):493-6. doi: 10.1038/nbt0506-493. Nat Biotechnol. 2006. PMID: 16680120 No abstract available.
Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial.
Emanuel EJ, Miller FG. Emanuel EJ, et al. Am J Bioeth. 2007 Feb;7(2):76-81. doi: 10.1080/15265160601111800. Am J Bioeth. 2007. PMID: 17366206 Review.

See all similar articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon